DNA Sequencing Market Size, Share, and Analysis By Product & Services (Products {Instruments & Consumables} and Services), By Technology (Sanger Sequencing, Next Generation Sequencing (NGS), and Others), By Type (Whole Genome/Exome Sequencing, Epigenetics, Targeted Sequencing and Others), By Workflow (Pre-sequencing, Sequencing, and Data Analysis), By Application (Drug Discovery & Development, Diagnostics and Others), By End-user (Biotechnology & Pharmaceutical Companies, Contract Research Organizations (CROs) and Others), and Regional Forecast till 2032

DNA sequencing is the process of determining the exact order of nucleic acid residues in the DNA molecules. The DNA sequences offer clear insights for the identification of clinically relevant mutations to detect the risk of cancer and genetic diseases. Moreover, DNA sequencing technology has more comprehensive applications in drug discovery & development, treatment responses, personalized medicine, evolution biology, and forensic sciences.

The market for DNA sequencing has witnessed tremendous growth since the commercialization of the Sanger sequencing method by Applied Biosciences. The advancements introduced in the nucleotide sequencing technologies is considered as the revolutionizing factor that drives the adoption of sequencing technologies in the field of molecular biology for various applications.

The conceptualization of next-generation sequencing and third-generation sequencing has significantly replaced the higher volume of first-generation sequencing. High-throughput and faster results, cost-effectiveness, parallel analysis of millions of sequences, and the ability to precisely detect low variants are resulting in the rapid growth of new-generation technologies. The breakthroughs in genomic research spur the growth of the DNA sequencing market.

Other factors driving the industry expansion include the increased patient demand for precision medicine in developed countries, investment initiatives, rising regulatory approvals, extensive R&D initiatives, and the introduction of futuristic products, services, and bioinformatics tools.

• For instance, in January 2024, Orchid launched a commercially available whole genome sequencing service called preimplantation genetic testing (PGT) to understand the risk of genetic diseases in IVF embryos.

Furthermore, strategic initiatives adopted by industry players for expanding the usage of DNA sequencing technologies in emerging markets is anticipated to propel the market growth in coming years.

• For instance, in May 2023, Thermo Fisher Scientific Inc., and Pfizer Inc. collaborated to improve access to DNA testing for breast and lung cancer patients in more than 30 countries of Asia, Latin America, and the Middle East & Africa.

However, the dynamics and complexity in the interpretation of sequencing results and false detection of DNA base pairs can potentially hamper the growth of the market.          

Impact of COVID-19 on the DNA Sequencing Market

During the COVID-19 pandemic, the DNA sequencing market encountered slight negative growth in the initial stage. The worldwide lockdowns, supply chain disruptions, resource reduction in the manufacturing, and other restrictions led to the negative expansion of the market in the early 2020.

However, being the first pandemic of the post genomic-era, launches of various genomic projects to understand the SARS-CoV-2 mechanism for the diagnosis and drug discovery led to the wide implementation of genomics technologies including DNA sequencing. Such initiatives increased the usage of DNA sequencing products and services in late 2020, which helped boost market growth. In 2021, the market grew substantially, returned to pre-pandemic levels in 2022, and is expected to grow continuously over the coming years.

Segmentation

Key Insights

The report covers the following key insights:

• Overview of DNA Sequencing Platforms


• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)


• Overview: Grants, Funding, and New Projects in Genomics


• Prevalence of Key Conditions - By Key Countries/Regions, 2023


• Impact of COVID-19 on the Market

Analysis by Technology

Based on technology, the market is classified into Sanger Sequencing, Next Generation Sequencing (NGS), and others. The Next Generation Sequencing (NGS) segment held a significant share of the market. The key benefits, including high fidelity, scalability, low cost, and faster sequencing, are driving the adoption of next-generation sequencing over Sanger sequencing. Rising number of liquid biopsy tests for cancer detection, carrier screening to prevent genetic diseases, and non-invasive prenatal screening are contributing to the growth of the segment. Moreover, the increasing launch of new kits and assays for target and gene-specific sequencing resulted in broader applications, thereby propelling the demand and adoption of NGS.

• For instance, in September 2023, Pillar Biosciences Inc. launched oncoReveal Core LBx, a next-generation sequencing (NGS) kit for liquid biopsy-based tumor profiling.

The others segment, including PacBio SMRT technology and Oxford Nanopore sequencing, is anticipated to grow rapidly over the projected years. The ability to detect the sequences without breaking and amplifying enable accurate detection. Such sophisticated approaches are increasingly used in DNA methylation and other epigenomics applications. Hence, the growth in the R&D of epigenetics and nutrigenomics is expected to boost the segment growth.

Regional Analysis

North America dominated in the global DNA sequencing market and expected to continue the dominance over the projected years. The presence of major players such as Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., PerkinElmer Inc., and huge R&D investments and initiatives for whole genome sequencing, transcriptomics, and oncology are significant factors contributing to the growth of the regional market.

• For instance, in January 2024, Illumina, Inc. and Janssen Research & Development, LLC, collaborated to develop novel molecular residual disease (MRD) assay, a whole-genome sequencing to detect circulating tumor DNA (ctDNA) to multi-cancer research detection.

The Asia Pacific market is expected to witness faster growth during the forecast period. The key factor driving the growth is the regional players’ focus on establishing DNA sequencing services and kits in collaboration with major players. Additionally, rising government initiatives to enhance the growth of genomic sector is expecting to increase the demand for DNA sequencing in the region.

• For instance, in February 2022, Singapore's Ministry of Trade and Industry (MTI) and India's Department of Science and Technology (DST) collaborated for genome and bioinformatics research to map Asian genome to understand the disease mechanism in Asian genes. The collaboration would allow both the organizations in the countries to launch joint genome research projects.

Key Players Covered

The report includes the profiles of key players such as Illumina, Inc., Thermo Fisher Scientific Inc., Novogene Co, Ltd., Agilent Technologies, Inc., Oxford Nanopore Technologies plc., PacBio, QIAGEN, PerkinElmer Inc., Azenta US, Inc, and other prominent players.

Key Industry Developments

• In September 2023, Integrated DNA Technologies, Inc. launched xGen NGS products specially designed for Ultima Genomics UG 100 platform. The xGen NGS products include primers, adapters, and universal blockers for various applications.


• In July 2023, Integrated DNA Technologies, Inc. launched xGen Respiratory Virus Amplicon Panel. The single panel can detect viral respiratory variants, including SARS-CoV-2, Respiratory Syncytial Virus (RSV) A, RSV B, Influenza A H1N1, Influenza A H3N2, and Influenza B.


• In March 2023, Illumina, Inc. launched high-performance, long-read, human whole-genome sequencing (WGS) assay. The assay is compatible with lllumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems.


• In October 2021, Promega Corporation launched ProDye Terminator Sequencing System. The system is designed for use with Promega Corporation’s any electrophoresis device.